help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Farnsworth, W. H.
Right arrow Articles by Brewer, H. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Farnsworth, W. H.
Right arrow Articles by Brewer, H. B., Jr

Journal of Clinical Endocrinology & Metabolism, Vol 65, 546-550, Copyright © 1987 by Endocrine Society

ARTICLES

Testicular function in type II hyperlipoproteinemic patients treated with lovastatin (mevinolin) or neomycin

WH Farnsworth, JM Hoeg, M Maher, EH Brittain, RJ Sherins and HB Brewer Jr

Steroid synthesis requires cholesterol derived from de novo synthesis or plasma lipoproteins. Low density lipoproteins appear to be the major contributor of cholesterol for steroid synthesis in man. Patients with disorders of low density lipoproteins or the low density lipoprotein receptor have reduced cortisol production in response to ACTH. Therapeutic agents designed to lower plasma cholesterol could, therefore, adversely affect steroid hormone production. Lovastatin (mevinolin) is a new hypolipidemic agent which blocks cholesterol synthesis by competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. In beagle dogs, lovastatin at 40-180 times the clinically effective dose in man, has been associated with an increase in spontaneous testicular atrophy. Accordingly, the effect of lovastatin on testicular function and lipoprotein levels was studied in 16 hyperlipidemic men in a randomized, double blind, cross-over study with another hypolipidemic agent, neomycin. Serum testosterone, PRL, LH, and FSH; LHRH-stimulated LH and FSH concentrations; and testicular size were measured, and semen analyses were made. We found no evidence that lovastatin had adverse effects on testicular function despite significant alterations in plasma lipoprotein concentrations.


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
S. A Linnebur and W. H Hiatt
Probable Statin-Induced Testicular Pain
Ann. Pharmacother., January 1, 2007; 41(1): 138 - 142.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
J. S. MacDonald and M. M. Halleck
The Toxicology of HMG--CoA Reductase Inhibitors: Prediction of Human Risk
Toxicol Pathol, February 1, 2004; 32(2_suppl): 26 - 41.
[Abstract] [PDF]

Home page
 J. Nutr.Home page
Y. Kido, S. Hiramoto, M. Murao, Y. Horio, T. Miyazaki, T. Kodama, and Y. Nakabou
{epsilon}-Polylysine Inhibits Pancreatic Lipase Activity and Suppresses Postprandial Hypertriacylglyceridemia in Rats
J. Nutr., June 1, 2003; 133(6): 1887 - 1891.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
L. A. Dostal, P. Juneau, and C. E. Rothwell
Repeated Analysis of Semen Parameters in Beagle Dogs during a 2-Year Study with the HMG-CoA Reductase Inhibitor, Atorvastatin
Toxicol. Sci., May 1, 2001; 61(1): 128 - 134.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1987 by The Endocrine Society